Glancy Binkow & Goldberg LLP
announces that it is investigating potential claims on behalf of shareholders of
(“Chemed” or the “Company”) (NYSE:CHE) concerning possible breaches of fiduciary duties by the Company or its fiduciaries. Chemed, through its subsidiaries, operates in the healthcare and repair and maintenance fields in the United States. The Company’s Vitas segment offers hospice and palliative patient-care services through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Please contact us at (212) 682-5340, toll-free at (888) 773-9224, or at
to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
The investigation is related to allegations that Chemed billed Medicare for unnecessary and fraudulent treatments – including billing for hospice care for patients who were not terminally ill – and whether the Company’s board of directors breached their fiduciary duties or allowed Chemed to engage in potential violations of the federal False Claims Act. In May 2013, the United States Department of Justice filed a lawsuit under the False Claims Act against Chemed and its affiliates, alleging that the Company systematically defrauded Medicare.
If you purchased Chemed shares and still hold those shares, if you have information or would like to
about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact
, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact
, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to
, or visit our website at
. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.